FILE:JNJ/JNJ-8K-20070207141219.txt.gz
EVENTS:	Other Events
TEXT:
ITEM: Other Events
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 1, 2007 JOHNSON & JOHNSON (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Juris- (Commission (IRS Employer diction of Incorporation) File Number) Identification No.) One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: 732-524-0400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 8.01. Other Items. On February 1, 2007, the Company announced the closing of its previously announced acquisition of Conor Medsystems, Inc., a cardiovascular device company with a unique controlled drug delivery technology, for a purchase price of $1.4 billion. The Company expects to incur an estimated one-time after-tax charge of approximately $600 million, or $0.21 per share, reflecting the write-off of in-process research and development charges. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JOHNSON & JOHNSON (Registrant) Date: February 1, 2007 By: /s/ S.J. Cosgrove S. J. Cosgrove Controller (Principal Accounting Officer) EXHIBIT INDEX Exhibit No. Description 99.1 Press release dated February 1, 2007.

Exhibit 99.1 Media Contacts: Jeffrey J. Leebaw Marc Monseau (732) 524-3350 (732) 524-1130 (732) 821-6007 Investor Contacts: Louise Mehrotra Stan Panasewicz Lesley Fishman (732) 524-6491 (732) 524-2524 (732) 524-3922 FOR IMMEDIATE RELEASE Johnson & Johnson Completes Acquisition of Conor Medsystems, Inc. New Brunswick, N.J., February 1, 2007 - Johnson & Johnson (NYSE: JNJ) today announced the closing of its previously announced acquisition of Conor Medsystems, Inc., a cardiovascular device company with a unique controlled drug delivery technology. "The completion of the acquisition of Conor Medsystems adds an important platform to our capacity to address cardiovascular and vascular disease globally," said Nicholas J. Valeriani, Worldwide Chairman, Medical Devices and Diagnostics, Johnson & Johnson. The Conor Medsystems CoStar* Stent provides for drug elution from a cobalt chromium stent with a fully bioabsorbable polymer, and employs a unique site-specific drug delivery technology potentially applicable with other therapeutic agents in the treatment of other conditions. "We look forward to exploring the potential for this novel reservoir technology in combination with other pharmaceutical agents and delivery systems as we seek new and better ways to address issues of cardiovascular and vascular disease," Valeriani concluded. Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. The more than 200 Johnson & Johnson operating companies employ approximately 122,000 men and women and sell products throughout the world. *The CoStar(r) Stent is not available for sale in the United States where it is an investigational device limited by law to investigational use. # # # (This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov or on request from the Company. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.) ###


